Compare Sanofi SA (SNY) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TORM plc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while TORM plc trades at $29.89 (market cap $2.99B). The key difference: Sanofi SA is far larger — about 35.1× TORM plc's market cap, and TORM plc pays the higher dividend (9.62%). Which is the better fit depends on your goals.
| SNY | TRMD | |
|---|---|---|
Market Cap | $104.83B | $2.99B |
Sector | Health | Technology |
52-Week High | $52.34 | $34.87 |
52-Week Low | $41.33 | $17.50 |
Enterprise Value | $121.32B | $3.88B |
Dividend Yield | 5.5% | 9.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TRMD trades at $29.08, up 2.21% today, with a neutral technical signal. The company reported strong profitability with a 24.41% net income margin and a low P/E of 8.34. Recent earnings showed a Q1 2026 miss but Q4 2025 beat, with Q2 2026 results pending. Cash flow from operations remains robust at $552 million in 2026, though net cash flow is negative. A $0.70 dividend for H1 2026 is scheduled, reflecting shareholder returns.
Outlook is positive due to strong fundamentals and 100% buy ratings from analysts, but risks include earnings volatility and negative net cash flow. The stock offers value with attractive valuation metrics and dividend yield, though investors should monitor Q2 earnings and cash flow trends for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
